Why the study?
Does stopping slow-release oxprenolol prevent rebound beta-adrenoceptor hypersensitivity compared to conventional oxprenolol in young normotensive subjects?
Does stopping slow-release oxprenolol prevent rebound beta-adrenoceptor hypersensitivity compared to conventional oxprenolol in young normotensive subjects?
Stopping both slow-release and conventional oxprenolol causes rebound beta-adrenoceptor hypersensitivity, challenging previous reports that slow-release formulations avoid this effect.
Answers are grounded in this paper and cite their sources.
Rebound hypersensitivity follows withdrawal of either oxprenolol formulation; challenges prior claims for slow-release mitigation and leaves open confirmation in target populations.
Using isoprenaline and glyceryl trinitrate (GTN) induced tachycardia we have compared the rebound beta-adrenoceptor hypersensitivity on stopping slow-release and conventional oxprenolol in young normotensive subjects. Heart rate on standing with GTN rose after stopping slow-release and conventional oxprenolol to peak levels on day 2 or 3 significantly greater than corresponding control levels off treatment on day 5. The isoprenaline CD25 (the dose required to increase heart rate by 25 beats/min) fell after stopping conventional oxprenolol to a significantly lower level on day 3 than the control level off treatment on day 5. Contrary to a recent report describing no rebound beta-adrenoceptor hypersensitivity on stopping slow-release oxprenolol we have demonstrated it after stopping slow release as well as conventional oxprenolol.
No takes yet. Share an insight, caveat, or question.
Singh et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: